Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study 2

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) on chronic statin therapy. Patients are randomized into two groups: atorvastatin pre-treatment group (80mg atorvastatin seven days before PCI) and control group (PCI without atorvastatin pretreatment, chronic statin treatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

This randomized study investigates potential protective effect of high dose atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) and chronic statin therapy.

Two arms:

1. atorvastatin pre-treatment group (80mg atorvastatin for seven days)
2. control group (without atorvastatin pre-treatment, chronic statin treatment)

Primary endpoint:

Periprocedural myocardial infarction measured by troponin I level (time frame 24 hours)

Secondary endpoint:

Periprocedural myocardial infarction measured by creatine kinase myocardial band (time frame 24 hours)

Inclusion Criteria:

• Indication for percutaneous coronary intervention
• Informed consent
• Chronic statin therapy

Exclusion Criteria:

• Acute coronary syndrome in last 14 days
• Renal insufficiency (creatinine more 150 umol/l)
• Diseases severely limiting prognosis
• Previous participation in this study
• Chronic occlusion of the coronary artery, bypass intervention, left main intervention
• Chronic statin treatment with atorvastatin 80mg daily and rosuvastatin